Cost-Effective Management of Diabetes

First-Line Foundation: Metformin

The American Diabetes Association recommends metformin as the initial agent for diabetes management, costing $1-5 per month for maximum doses, making it the most cost-effective diabetes medication available 1, 2
Generic metformin 850 mg or 1,000 mg immediate-release formulations cost approximately $2 per month for maximum approved daily doses 1
Extended-release formulations are significantly more expensive ($32-160 per month) and offer no substantial clinical advantage over immediate-release for most patients 1

Sulfonylureas provide the most dramatic cost savings compared to Januvia, which costs $500-626 per month 1, 2
Glimepiride 4 mg costs $2-4 per month for maximum dose, making it the most cost-effective sulfonylurea option 1, 2
Glipizide 10 mg immediate-release costs $5-6 per month for maximum dose 1, 2
Glyburide 5 mg costs $7-11 per month for maximum dose 1, 2
Sulfonylureas reduce HbA1c by approximately 1% when added to metformin, comparable to DPP-4 inhibitors 2
The American College of Clinical Endocrinologists recommends monitoring HbA1c every 3 months until stable, then every 6 months 2

If Jardiance was prescribed solely for glucose control, sulfonylureas remain the most cost-effective alternative, with cost savings of $540-683 per month compared to empagliflozin 1, 2, 4
The American Heart Association recommends considering the cardiovascular and renal protective effects of SGLT2 inhibitors when determining the most cost-effective alternative 4, 5
Cost-effectiveness analyses show SGLT2 inhibitors as first-line therapy cost $508,000 per QALY gained, requiring 70-90% price reduction to reach acceptable thresholds 5

Alogliptin 25 mg costs $154-234 per month, making it the least expensive DPP-4 inhibitor 1, 2
Sitagliptin 100 mg costs $500-626 per month 1
Saxagliptin 5 mg costs $452-565 per month 1
Linagliptin 5 mg costs $485-606 per month 1
The American College of Clinical Endocrinologists recommends considering the cost-effectiveness of DPP-4 inhibitors when determining the most cost-effective alternative 4

The American Diabetes Association recommends ensuring metformin is optimized before adding other agents 1, 3, 2
The American College of Clinical Endocrinologists recommends adding glimepiride 1-2 mg daily with breakfast and titrating to 4-8 mg based on glucose response 2
The American Heart Association recommends providing hypoglycemia education and glucose tablets when prescribing sulfonylureas 2

The American College of Clinical Endocrinologists recommends considering the addition of NPH insulin, which costs approximately $25 per vial, as a more cost-effective option than adding expensive branded agents 2